Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT00415506
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Orbital Disease
  • Scleritis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.

Study Details

The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.

Key Dates

Start date
Jan 31, 2007
Status verified
Aug 2013
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Scleritis
    Subjects with Scleritis
  • Experimental: Orbital Inflammation
    Subjects with Orbital Inflammation

Primary Outcome Measure

Reduction of Medications [ Time Frame: 24 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health & Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By research site
Oregon Health & Science University· Portland, OR